Newsletter Tool

Featured Story

Qiagen slashes full-year forecast as COVID test sales fall 17% in Q2

By Andrea Park

In comparison to an original prediction of about 18% to 20% sales growth for the whole year, Qiagen is now expecting to bring in a much more modest 12% bump in year-over-year sales.

Gilead's Veklury shows 'no antiviral effects,' small WHO study says as company stands by COVID med

By Noah Higgins-Dunn

Gilead's Veklury, also known as remdesivir, and hydroxychloroquine didn’t significantly clear the virus from hospitalized COVID-19 patients or affect the degree of respiratory failure and inflammation over standard of care, a small follow-up study to the World Health Organization's Solidarity trial found.

National Nurses United calls on CDC to reinstate masking policies after COVID-19 case spike

By Robert King

The union National Nurses United is concerned about the rising COVID-19 cases across parts of the U.S. and wants the CDC to reinstate universal masking policies.

Ena starts phase 1 trial of COVID-19-preventing nasal spray

By Nick Paul Taylor

Ena Respiratory has begun a phase 1 clinical trial of its nasal spray for the prevention of COVID-19 and other respiratory viral infections. The study is expected to wrap up in the third quarter.

COVID-19 tracker: J&J, AZ eye tweaks to vaccines, report says; Qiagen cuts financial expectations

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Johnson & Johnson and AstraZeneca are said to be weighing potential changes to their vaccines to address concerns over blood clots. Qiagen had to cut its 2021 financial expectations as testing demand dries up. And more.

COVID-19 Tracker